D iabetes mellitus and cardiovascular diseases develop in concert with metabolic abnormalities mirroring and causing changes in the vasculature. More than half of the mortality and a vast amount of morbidity in people with diabetes mellitus are related to cardiovascular diseases. 1 The European Society of Cardiology (ESC) Task Force recommends the use of noninvasive testing for risk stratification of diabetic patients with known or suspected coronary artery disease (CAD), which should be performed according to individual needs and clinical judgment and not meant as a general recommendation to be undertaken by all patients. 1 In fact, in asymptomatic subjects, routine screening for CAD is controversial. 2 Myocardial ischemia may be detected by exercise electrocardiography, myocardial perfusion imaging, or stress echocardiography. Stress echocardiography can, then, play a key role in the optimal identification of high-risk diabetic patients, providing similar diagnostic 3 and prognostic information in patients with and without diabetes mellitus, independently of age. 4 Moreover, stress echocardiography allows effective risk assessment in both diabetics and nondiabetics with intermediate-to high-threshold ischemic exercise electrocardiography. 5 Nevertheless, the normal test result predicts a less favorable outcome in the diabetic population. 4, 5 The present multicenter, observational study was aimed at assessing whether the established stress echocardiography parameters related to outcome showed a different behavior in diabetics and nondiabetic patients with known or suspected CAD.
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Methods Patients
From the prospective data bank of 2 different Italian institutions (Lucca and Pisa), 14 463 patients tested with stress echocardiography between 1995 and 2011 were initially selected. Part of this sample (5456 subjects) was previously published 4 and the current study represents an extension of follow-up. No patient had significant valvular or congenital heart disease, significant comorbidity reducing life expectancy to <1 year, and inadequate acoustic window. All patients referred to the laboratories for stress echocardiography underwent a rest echocardiogram as recommended by guidelines and good clinical practice to assess acoustic adequacy. Three-hundred twenty-three patients were lost to follow-up. The remaining 14 140 patients, of whom Stress Echocardiography and Diabetes Mellitus 2835 (20%) were diabetics, formed the study population. Indication to stress echocardiography was suspected CAD in 8469 (60%) and risk stratification of known CAD (ie, history of acute coronary syndromes or coronary revascularization and angiographic evidence of >50% diameter coronary stenosis) in 5671 (40%) individuals. The subset of patients lost to follow-up did not differ from the sample under investigation as regards to age, stress echo results (extent of ischemia), and left ventricular function. The stressor used (2160 exercise, 2642 dobutamine, and 9338 dipyridamole) was chosen on the basis of specific contraindications, local facilities, and physician's preferences. Pharmacological stress echocardiography was used when exercise electrocardiography result was unfeasible, nondiagnostic, or inconclusive. The choice of the pharmacological stressor was made on the basis of potential relative contraindications of one over the other and on the basis of a gradient of tolerability, being dipyridamole safer 6 and more feasible than dobutamine, particularly in patients with hypertension. 7 The diagnosis of diabetes mellitus was based according to standard criteria: presence of classic symptoms of hyperglycemia and an abnormal blood test (a plasma glucose concentration, ≥7 mmol/L [or 126 mg/dL] or ≥11.1 mmol/L [or 200 mg/dL] 2 hours after a 75-g glucose drink) or on medication; in a patient without classic symptoms, diagnosis was also made by 2 abnormal blood tests on separate days. 8 Stress echocardiography was performed on antianginal medical therapy in 5249 (37%; β-blockers in 3231, calcium antagonists in 2218, or nitrates in 2098) and off therapy in 8891 (63%) patients. Informed consent was obtained from all patients before testing, and the study protocol was approved by the institutional ethical committee. Stress echo data were collected and analysed by stress echocardiographers not involved in patient care. All investigators of contributing centers passed quality control criteria for regional wall motion before entering the study as previously described. 9 Hypertension, 10 hypercholesterolemia, 11 and smoking habit 12 were defined according to standard definitions.
Patients were followed up for a median of 30 (first quartile, 9; third quartile, 63) with a minimum predefined follow-up time of 3 months.
Stress Protocol
Exercise stress echo was conducted using a semisupine bicycle ergometer with 25 W incremental loading every 2 minutes. Dipyridamole (≤0.84 mg/kg for 10 minutes with coadministration of atropine ≤1 mg or ≤0.84 mg/kg mg for 6 minutes) and dobutamine (≤40 μg/kg per minute with coadministration of atropine ≤1 mg) stress echo were performed according to the well-established protocols. 13
Echocardiographic Analysis
Echocardiographic images were semiquantitatively assessed using a 17 segments, 4-point scale model of the left ventricle. 14 During the procedure, blood pressure and ECG were recorded each minute. A wall motion score index (WMSI) was derived by dividing the sum of individual segment scores by the number of interpretable segments. Ischemia was defined as stress-induced new and worsening of pre-existing wall motion abnormality or biphasic response (ie, lowdose improvement followed by high-dose deterioration). Inotropic reserve was defined as any improvement of WMSI during stress in the absence of inducible ischemia. Necrotic pattern was akinetic or dyskinetic myocardium with no thickening during stress. An hypokinetic segment that does not worsen during ischemic challenge is considered a rest WMA. A test was normal in case of no rest and stress wall motion abnormality. A test was considered positive for ischemia when at least 2 adjacent segments of the same vascular territory showed an increment of WMSI (worsening of regional function) of at least 1 point at peak stress.
Follow-Up
Follow-up data were obtained from at least 1 of 4 sources: review of the patient's hospital record, personal communication with the patient's physician and review of the patient's chart, a telephone interview with the patient's relatives conducted by trained personnel. Death certificates were obtained in case of need. Mortality was the only end point. Coronary revascularization (surgery or percutaneous interventions) was also recorded; however, it was not identified as clinical event. To avoid misclassification of the cause of death, 15 overall mortality was considered. Follow-up data were analyzed for the prediction of survival (death).
Statistical Analysis
Continuous variables are expressed as mean±SD. Two-sample comparisons were performed using t test if variables were normally distributed, the Mann-Whitney U test for not normally distributed data, and the χ 2 test for categorical data. Death rates were estimated with Kaplan-Meier curves and compared by the log-rank test. Patients undergoing coronary revascularization were censored at the time of the procedure: revascularization changes the natural history of coronary disease; it may modify outcome and it may have high mortality in high-risk subsets. What happens after a revascularization cannot be attributed to the diagnostic and prognostic yield of a test. Such an approach allows to obtain an independent distribution of the observed cases assuming a uniform risk across all the characteristics of a given sample. Annual event rates were obtained from Kaplan-Meier estimates to take censoring of the data into account. To assess the revascularization rates, these were estimated with cumulative incidence function rather than the survival function, using competing-risk regression by the method of Fine and Gray. 16 Because death was the event that occurred instead of the failure event of interest, we cannot treat these as censored. For comparing the subdistribution for each cause across groups the Gray's test was used. 17 Annual event rates were obtained from Kaplan-Meier estimates to take censoring of the data into account. The association of selected variables with outcome was assessed with the Cox's proportional hazard model using univariate and stepwise multivariable procedures. A significance of 0.05 was required for a variable to be included into the multivariable model, whereas 0.1 was the cutoff value for exclusion. Hazard ratios with the corresponding 95% confidence interval were estimated. Statistical significance was set at P<0.05. The following covariates were analyzed: age, sex, left bundle branch block, arterial hypertension, hypercholesterolemia, smoking habit, prior myocardial infarction, prior coronary artery bypass grafting, prior percutaneous coronary intervention, ongoing anti-ischemic therapy (anti-ischemic therapy is defined as any treatment alone or in combination of calcium channel blockers, β-blockers or nitrates), rest WMA, rest WMSI, ischemia at stress echo, and WMSI at peak stress. The impact of stress echo variables on reclassification of patient risk with respect to total cardiac events was determined using net reclassification improvement. 18 Statistical Package for the Social Sciences (SPSS release 13.0, Chicago, IL) and R software were used for the analysis.
Results
Stress Echocardiography
Clinical and echocardiographic characteristics of the study population are reported in Table 1 . Diabetics were tested more frequently under antianginal therapy than nondiabetics (46% versus 35%; P<0.0001; Table 1 ). Ischemia was assessed in 3412 (24%) subjects: 2046 (17%) with rest WMA and 1366 (11%) without rest WMA. Ischemia was more frequent in diabetic than in nondiabetic patients (27% versus 23%; P<0.0001; Table 1 ); WMSI at peak of stress was higher in diabetics than in nondiabetics (1.32±0.40 versus 1.25±0.36; P<0.0001). A necrotic pattern was found in 3729 (26%) subjects: 29% of diabetics and 26% of nondiabetics (P=0.002; Table 1 ). A normal test was detected in 7000 individuals (50%), being more frequent in nondiabetics (51% versus 44%; P<0.0001; Table 1 ). In Table 2 , the incidence rate of prior myocardial infarction, coronary artery bypass graft, and percutaneous Stress Echocardiography and Diabetes Mellitus intervention is reported. The rate is comparable between diabetics and nondiabetics on and off therapy. It is, however, interesting to note that patients on medical therapy irrespective of metabolic status had a significantly higher incidence of previous myocardial infarction and revascularizations.
Outcomes
During follow-up, 1213 (9%) patients died: 334 diabetics and 879 nondiabetics (12% versus 8%; P<0.0001). According to the physician's judgment, 3272 (23%) patients underwent coronary revascularization (1137 surgery, 2135 percutaneous intervention) after a median of 63 days (interquartile range, 8-311 days) from the index stress echo. Revascularization was performed in 793 (28%) diabetics and in 2479 (22%) nondiabetics (P<0.0001). The revascularization rate was higher in diabetics than in nondiabetics both considering patients with ischemia (P=0.02) and patients without ischemia (P<0.0001) at stress echo ( Figure 1 ).
Outcome Prediction
Annual mortality was 2-fold higher in diabetic than in nondiabetic patients (4.2% versus 2.1%; P<0.0001). The 5-year mortality was 21% in diabetics with known CAD and 15% in diabetics with suspected CAD (P<0.0001); it was 13% in nondiabetic with known CAD and 7% in nondiabetics with suspected CAD (P<0.0001; Figure 2 ). Of note, 5-year survival did not significantly differ between diabetics with suspected CAD and nondiabetics with known CAD (P=0.14). The univariable and multivariable prognostic indicators in patients with and without diabetes mellitus are shown in Table 3 . Ischemia at stress echo, rest WMA, and age independently predicted mortality in both patients groups. Additional independent prognostic indicators were male sex and antischemic therapy at time of test in nondiabetic patients (Table 3 ). Analyzing data according to prognostically important echocardiographic parameters, such as ischemia at stress echo and rest WMA, an effective risk stratification was obtained in diabetic as well as nondiabetic patients ( Figure 3 ): both ischemia and rest WMA were predictive of unfavorable outcome. However, the mortality rate associated with ischemic test was higher in both diabetics and nondiabetics with and without rest WMA ( Figure 3 ). Antischemic therapy at time of testing exerted a different prognostic impact on the diabetic and nondiabetic population. In fact, the 5-year survival did not significantly differ between diabetic patients evaluated on and off therapy both considering the sample with (27% versus 28%; P=0.63) and without inducible ischemia (19% versus 14%; P=0.09; Figure 3 ); conversely, it was markedly lower in nondiabetics tested on therapy both considering the group with (17% versus 14%; P=0.002) and without ischemia (11% versus 6%; P<0.0001; Figure 4 ).
Considering the subset with stress echo negative for ischemia, antischemic therapy predicted significantly increased annual mortality in nondiabetic patients with (3.8% versus 3.1%; P=0.04) or without rest WMA (1.6% versus 0.9%; P<0.0001); however, it failed to do so in diabetic patients with (5.7% versus 5.8%; P=0.89) or without rest WMA (2.6% versus 1.9%; P=0.10).
Reclassification data for diabetics with and without death are summarized in Table 4 . In particular, significant (P<0.001) net gain in reclassification proportion of 0.035 was observed in the model including the stress echo results for subjects who did not experience an event (with 172 individuals reclassified down and 83 reclassified up). The Net Reclassification 
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Index including stress echo values was estimated be 0.047 (P=0.028). Based on the Net Reclassification Index and its components, the addition of stress echo results to the prediction model including only risk factors (hypertension, hypercholesterolemia, smoking habit, and age) actually improved classification for a net of 3.5% of individuals who did not experience events, with no net loss for events (P=0.564). In nondiabetics, significant (P<0.001) net gain in reclassification proportion of 0.048 was observed in the model including the stress echo values ( Table 5 ). Based on the Net Reclassification Index and its components, the addition of stress echo results to the prediction model including only risk factors actually improved classification for a net of 2.1% (P<0.001) of individuals who did not experience events, and for a net of 2.7% (P=0.007) of individuals with events.
Discussion
In 2004, an estimated 3.4 million people died from consequences of high fasting blood sugar 19 and World Health Organization projects that diabetes mellitus will be the seventh leading cause of death in 2030. 20 Therefore, the prognostic assessment of diabetic patients is of primary clinical importance. The results of this study indicate that stress echocardiography is a useful prognostic tool in diabetic patients. A normal study with any type of stressor is a marker of low risk; however, in the diabetic group, the risk is higher. Inducible ischemia at stress echocardiography is an independent predictor of mortality, and the level of risk is related to the extent of the inducible abnormality as expressed by peak WMSI. However, the presence of rest WMA is an independent predictor of mortality in both patient groups. Medical therapy at time of testing confers a higher risk of mortality in nondiabetics but does not play any prognostic role in diabetics. The present study expands our previous report 4 by analyzing a much larger sample and including only mortality as an end point with a longer follow-up. Moreover, medical therapy at time of testing, which is a parameter of ischemia severity, did not seem to affect outcome in the diabetic group. The lack of modulation of stress testing by medical therapy suggests that inducible ischemia is more severe in the diabetic group.
Comparisons With Previous Studies
Several studies have addressed the prognostic ability of stratification of noninvasive imaging in patients with and without diabetes mellitus. In particular, in patients with overt resting ischemic cardiomyopathy, the presence of myocardial viability recognized by dobutamine stress echocardiography independently predicted improved outcome after revascularization in nondiabetics as well as in diabetic patients after revascularization. 21 Also in unselected patient populations with proven or suspected CAD, a clear refinement of prognosis can be obtained with stress echocardiography, first and foremost on the basis of classical wall motion abnormalities, 4,22-27 which place the patients in a high-risk subset for cardiovascular events. The incremental prognostic information provided by stress echocardiography is highest in patients with intermediate-to-high threshold positive exercise electrocardiography test results. 5 However, in diabetic patients, differently from nondiabetic subjects, a negative test result based solely on wall motion criteria is associated with less benign outcome. 4 In a study on 2349 diabetic patients investigated with dobutamine stress echocardiography, the mortality and cardiovascular morbidity were significantly higher in subjects with abnormal or ischemic test results. 26 Also, failure to achieve target heart rate and percentage of ischemic segments, an indicator of the extent of inducible ischemia, were independent predictors and incremental to clinical and rest echocardiographic variables for predicting adverse long-term outcomes. 26 In a more recent study assessing the long-term follow-up of stress echocardiography, dobutamine stress echocardiography provided restricted predictive value of adverse outcome in patients with diabetes mellitus who were unable to perform an adequate exercise stress test. 27 The authors also identified a warranty period of the test, which provided optimal risk stratification ≤7 years after initial testing. Repeated dobutamine stress echocardiography at that time might add to its prognostic value. 27 Stress myocardial perfusion imaging can be considered a viable alternative to stress echocardiography with the limitation of being less available, more expensive, and with potential long-term downstream detrimental effect because of ionizing radiations. 28 Stress myocardial perfusion imaging has been shown to have significant prognostic power for future cardiac events in the symptomatic diabetic population. In a large multicenter study enrolling 4755 patients (20% diabetic patients) who underwent exercise or pharmacological myocardial perfusion imaging for symptomatic CAD, abnormal stress myocardial perfusion imaging was found to be an independent predictor of cardiac events in both diabetic and nondiabetic sample. 29 Moreover, the number of abnormal segments (fixed or ischemic) was related to worse outcome 29 and this is consistent with the stress echocardiographic findings showing an ominous outcome for higher values of WMSI.
Clinical Implications
Information on the relative prognostic contribution of stress echocardiography in the diabetic and nondiabetic population could allow to optimize patient management. However, the prognostic information provided by stress echocardiography shows important differences in diabetic and nondiabetic population that should be taken into account in risk stratification. First, a normal test result implied less favorable survival among diabetic patients independently of whether they were studied on antianginal therapy. Second, an ischemic test conveyed markedly lower risk in both diabetics and nondiabetic without ischemia than in those with rest WMA. Finally, antischemic therapy at the time of testing exerted a different prognostic impact on the diabetic and nondiabetic population. In fact, the 5-year survival did not significantly differ between diabetic patients evaluated on and off therapy independently of test result. Such result is surprising and new because our previous reports have shown the detrimental effect of medical therapy at time of testing. 30 Ischemia remains the major determinant of outcome in diabetics and medical therapy does not modulate prognostically test results. It is conceivable that Medical therapy is given independent of the presence of symptoms or myocardial ischemia because diabetics are at high risk of CAD and its complications. Medical therapy does not protect the diabetic patient from myocardial ischemia: this may be one of the reasons for the 4-fold mortality rate in diabetic patients versus nondiabetics. This is only hypothetical because our study is not meant to address this issue but this observation has relevant clinical implications: anti-ischemic therapy may be less effective in diabetics and this should be taken into account when considering all the therapeutic options. These data confirm and support the clinical use of stress echocardiography for the assessment of mortality in diabetic and nondiabetic patients. However, no single optimal strategy has been identified for this high-risk set of patients. Recent ESC guidelines although demonstrating a pivotal role of noninvasive imaging for risk stratification do not recommend a universal diagnostic-prognostic algorithm. Exercise electrocardiography is of limited value in the diabetic population because exercise capacity is often impaired by peripheral vascular or neuropathic disease. However, when paired with an imaging technique it has been shown to risk stratify patients 25 and the ability of exercise was a parameter per se of better outcome when compared with pharmacological challenge. However, in asymptomatic patients, routine screening for CAD is controversial and it is not recommended by the American Diabetes Association because it does not improve outcomes as long as cardiovascular risk factors are treated. 2 The recommendation is not based on hard evidence but rather on the consensus of an expert panel. The recognized finding that 10% to 15% of asymptomatic diabetics indeed have CAD has led to proposing stress imaging for a more effective risk stratification. 31 The clinical management remains controversial: test prescription should be reserved for selected individuals in whom there is strong clinical suspicion of high-risk CAD and in those in whom medical treatment goals cannot be met. This would reduce the burden of testing with no clear prognostic benefit and potential downstream risks (acute side effects, radiations 
Study Limitations
Because of the long recruitment period, the outcome based on stress test results may have been potentially influenced by evolution of methodology, technology, and expertise and advances in medical and interventional treatments. In this study, there was no central reading. Stress echocardiography was interpreted in the peripheral centers and entered directly in the database. This system allowed substantial sparing of human and technological resources, but it also was the logical prerequisite for a largescale study designed to represent the realistic performance of the test rather than the results of a single laboratory, or even a Because the assessment of the echocardiograms was qualitative and subjective, variability in reading the echocardiograms might have modulated the results of individual centers. 14 However, all our readers in individual centers had lengthy experience in echocardiography and passed the quality control in stress echocardiography reading as previously described. 9 The test results available to the referring physicians may have influenced the clinical management of the patients, especially on coronary revascularization, but this may have only decreased the prognostic power of the test, because patients were censored at the time of the procedure. The study was not designed to address the effect of anti-ischemic therapy, therefore enrolling centers evaluated each single patient according to referring physician's prescriptions. This represents a major limitation to the present results because test result was available to the referring physician who may have modified medical therapy or indicated intervention in case of test positivity. This, again, may have reduced the prognostic power of stress echocardiography. The study was not designed to address any change in antidiabetic therapy or HbA1c control over time. This may have affected outcome in the diabetic group. All submaximal tests, by convention in our database, are considered negative. Such an approach would only lower the prognostic power of stress testing. Still we do not separate from our analysis these tests which may increase the number of false-negative tests. It is a choice, but it reflects a realistic approach to clinical practice, including only patients with 1 test and avoiding the analysis of the subset that may have been indicated a second different technique.
In the outcome analysis, follow-up was censored at the time of revascularization: revascularization may change the natural history of CAD and our aim was to assess the risk of death in a homogeneous sample.
Conclusions
Mortality is the most relevant end point in risk stratification and stress echocardiography is able to independently predict such a catastrophic event in diabetics as well as nondiabetic patients. Nondiabetics with a normal stress echo are at low risk for death, particularly if tested off therapy, whereas diabetics presented increased risk independently by ongoing therapy. The ischemic burden is strictly related to survival but better treatment strategies are warranted to treat the high-risk group of patients with diabetes mellitus. Medical therapy does not modulate prognostically test results in diabetics. Large databases are needed to help physicians in improving their diagnostic and prognostic acumen. This is a little piece of evidence in that direction. 32 
